Table 2.
Treatment administration and efficacy in both EP and IP arms
| Parameter | IP (n = 30) | EP (n = 32) | P value |
|---|---|---|---|
| Cycles | 0.064 | ||
| 1 | 1 (3.3%) | 0 | |
| 2 | 4 (13.3%) | 4 (12.5%) | |
| 3 | 2 (6.7%) | 0 | |
| 4 | 10 (33.3%) | 13 (40.6%) | |
| 5 | 5 (16.7%) | 3 (9.4%) | |
| 6 | 8 (26.7%) | 12 (37.5%) | |
| Average cycles | 4.3 | 4.6 | |
| Response | |||
| CR | 2 (6.7%) | 0 | |
| PR | 19 (63.3%) | 21 (65.6%) | |
| SD | 4 (13.3%) | 2 (6.3%) | |
| PD | 5 (16.7%) | 9 (28.1%) | |
| ORR (CR+PR) | 21 (70%) | 21 (65.6%) | 0.056 |
| DCR (CR+PR+SD) | 25 (83.3%) | 23 (71.9%) | 0.043 |
CR, complete response; DCR: disease control rate; EP, etoposide plus cisplatin; IP, irinotecan plus cisplatin; ORR: overall response rate; PD, progressive disease; PR, partial response; SD, stable disease.